Literature DB >> 25677671

Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review.

Linda van der Tol1, Marije L Sminia2, Carla E M Hollak1, Marieke Biegstraaten1.   

Abstract

BACKGROUND: Screening for Fabry disease (FD) increasingly reveals individuals without characteristic features and with a variant of unknown significance in the α-galactosidase A (GLA) gene. Cornea verticillata (CV) assessment, as a characteristic sign of FD, may be a valuable diagnostic tool to assess whether these individuals have a non-classical phenotype or no FD at all.
METHODS: We performed a systematic review to estimate the prevalence of CV in FD. Additionally, CV prevalence was assessed in the Dutch FD cohort. Data were stratified by gender and phenotype (classical, non-classical, uncertain, no-FD) using predefined criteria.
RESULTS: CV was assessed in 21 cohorts (n=753, 330 men, age 0-85 years). Pooled prevalence was 69% (74% men, 66% women). In six studies, 77 (19 men) individuals with a non-classical or uncertain diagnosis were identified. Individual data were available in 4/6 studies (n=66, 16 men). CV was present in 24% (n=16, 2 men). 101 (35 men) subjects from the Dutch cohort were grouped as classical, of whom 86% (94% men, 82% women including five women who used amiodarone) had CV. Of the 25 (11 men) non-classical patients, 4 (three men) had CV. Subjects in the uncertain and no-FD groups did not have CV.
CONCLUSIONS: CV is related to classical or biopsy-proven non-classical FD, with a very high sensitivity in classical men. Thus, presence of CV in an individual with an uncertain diagnosis of FD indicates a pathogenic GLA variant, in the absence of medication that may induce CV; if CV is absent, FD cannot be excluded. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Cornea; Diagnostic tests/Investigation; Epidemiology; Genetics

Mesh:

Substances:

Year:  2015        PMID: 25677671     DOI: 10.1136/bjophthalmol-2014-306433

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  5 in total

1.  Assessment of corneal topographic, tomographic, densitometric, and biomechanical properties of Fabry patients with ocular manifestations.

Authors:  Veysel Cankurtaran; Kemal Tekin; Ayse Idil Cakmak; Merve Inanc; Faruk Hilmi Turgut
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-01-08       Impact factor: 3.117

2.  In Patients with an α-Galactosidase A Variant, Small Nerve Fibre Assessment Cannot Confirm a Diagnosis of Fabry Disease.

Authors:  Linda van der Tol; Camiel Verhamme; Ivo N van Schaik; Anneke J van der Kooi; Carla E M Hollak; Marieke Biegstraaten
Journal:  JIMD Rep       Date:  2015-11-14

3.  Paediatric Fabry disease: prognostic significance of ocular changes for disease severity.

Authors:  Gisela Kalkum; Susanne Pitz; Nesrin Karabul; Michael Beck; Guillem Pintos-Morell; Rossella Parini; Marianne Rohrbach; Svetlana Bizjajeva; Uma Ramaswami
Journal:  BMC Ophthalmol       Date:  2016-11-16       Impact factor: 2.209

4.  Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.

Authors:  Nurcan Üçeyler; Nils Schröter; Waldemar Kafke; Daniela Kramer; Christoph Wanner; Frank Weidemann; Claudia Sommer
Journal:  PLoS One       Date:  2016-11-16       Impact factor: 3.240

5.  Retinal hyperreflective foci in Fabry disease.

Authors:  Yevgeniya Atiskova; Rahman Rassuli; Anja Friederike Koehn; Amir Golsari; Lars Wagenfeld; Marcel du Moulin; Nicole Muschol; Simon Dulz
Journal:  Orphanet J Rare Dis       Date:  2019-12-26       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.